COAG — Hemab Therapeutics Holdings, Inc.
—
Nasdaq ·
Health Care ·
Biotechnology ·
CIK 2114044 ·
Last close
$32.37
Market Cap
$1.51B
52W High
$36.61
52W Low
$23.00
ADV30
243,860
Next earnings
2026-08-14
Quarterly Fundamentals
Revenues vs Net Income (last 4 Q)
Assets vs Liabilities (last 4 Q)
| Period | Revenues | GrossProfit | OpIncome | NetIncome | Assets | Cash | Liabilities |
|---|---|---|---|---|---|---|---|
| Mar 2026 | — | — | — | — | — | — | — |
| Mar 2025 | 0 | — | -16,560,000 | -15,306,000 | — | — | — |
Balance + Analyst (yfinance extras)
Retained Earnings
$-204,545,000
Inventory
—
Receivables
$1,430,000
ST Investments
$113,671,000
EBIT TTM
$-40,172,000
Pretax Income TTM
$-38,171,000
Interest Exp TTM
—
Analysts
—
Annual Trend (SEC EDGAR, last 2y)
Revenues vs Net Income (last 2y)
| FY end | Revenues | OpIncome | NetIncome | Assets | Liabilities | Equity | OCF |
|---|---|---|---|---|---|---|---|
| Dec 2025 | 0 | -70,119,000 | -63,913,000 | 194,783,000 | 371,418,000 | — | -61,475,000 |
| Dec 2024 | 0 | -50,383,000 | -48,707,000 | 96,278,000 | 211,551,000 | — | -45,592,000 |
TTM Snapshot
Revenues TTM
—
NetIncome TTM
—
OpCashFlow TTM
—
Assets (Latest)
—
Forward EPS
$-2.45
Peers — same industry
| Ticker | Name | Market Cap | Last | Daily % |
|---|---|---|---|---|
| NVAX | NOVAVAX INC | $1.46B | $8.88 | — |
| IMCR | Immunocore Holdings plc | $1.57B | $30.88 | — |
| MAZE | Maze Therapeutics, Inc. | $1.57B | $28.43 | — |
| INBX | Inhibrx Biosciences, Inc. | $1.39B | $94.81 | — |
| VIR | Vir Biotechnology, Inc. | $1.69B | $10.03 | — |
News headlines (Yahoo Finance, 1h cache)
Hemab Therapeutics to Present Clinical and Preclinical Data from Multiple Blood Coagulation Programs at the ISTH 2026 Congress
2026-06-26 13:00 · Yahoo
Hemab Therapeutics Details Post-IPO Pipeline Push, Sutacimig Phase III Plans
2026-06-09 03:03 · Yahoo
Hemab Therapeutics to Participate in the 2026 Jefferies Global Healthcare Conference
2026-05-27 12:00 · Yahoo
Hemab Therapeutics Reports First Quarter 2026 Financial Results
2026-05-21 11:00 · Yahoo
Hemab Therapeutics Announces Closing of Upsized Initial Public Offering and Full Exercise of Underwriters’ Option to Purchase Additional Shares
2026-05-04 20:01 · Yahoo
Hemab Therapeutics IPO Debut Puts COAG And Pipeline Risks In Focus
2026-05-03 07:07 · Yahoo
Hemab Therapeutics Announces Pricing of Upsized Initial Public Offering
2026-04-30 22:55 · Yahoo
Recent Insider Activity
No insider activity indexed for this ticker.